GILEAD SCIENCES INC (GILD) Stock News
NASDAQ:GILD - Nasdaq - US3755581036 - Common Stock
GILD Latest News and Analysis
Why Gilead Sciences (GILD) Outpaced the Stock Market Today
The latest trading day saw Gilead Sciences (GILD) settling at $92.96, representing a +1.22% change from its previous close.
Can Gilead Sciences Sustain Its Growth Momentum in 2025?
GILD has performed well in the past six months, with new drug approvals, positive data readouts and strong quarterly results. While the fundamentals look solid, we advise investors to remain on the sidelines at current levels.
Goldman Sachs Thinks Mid-Cap Biotech MoonLake Could Soar Over 80%: Is Retail Watching Closely?
Oppenheimer has included MoonLake among its top biotech picks for 2025, alongside Capricor, Gilead, Kymera, Praxis, and Prothena.
Interesting GILD Put And Call Options For June 2027
Gilead Sciences, US government settle patent case over HIV prevention drugs
Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs Truvada and Descovy, according to a Wednesday filing in Delaware federal court. The settlement follows a victory for Gilead in a 2023 jury trial on the government's patent infringement allegations. Gilead General Counsel Deborah Telman said in a statement that the agreement "allows Gilead to continue to focus its resources on its mission to discover, develop, and deliver innovative therapeutics to people with life-threatening diseases."
April 17th Options Now Available For Gilead Sciences (GILD)
Gilead’s new HIV prevention drug lenacapavir will ‘change the face of HIV,’ says CEO Daniel O’Day
Gilead's chief executive calls lenacapavir a once in a decade medicine. The HIV treatment could push Gilead stock further up in 2025.
Gilead, LEO Pharma partner to develop programs for inflammatory diseases
The Danish company will be eligible to receive up to $1.7 billion in payments which include an upfront payment of $250 million from Gilead. In return, Gilead will have global rights to develop, manufacture, and commercialize the small molecule oral STAT6 (signal transducer and activator of transcription 6) program. Targeting STAT6 has shown potential preclinically to treat a broad population of patients with inflammatory conditions such as atopic dermatitis, asthma, and COPD, the statement said.
AMD downgraded, Nike upgraded: Wall Street's top analyst calls
AMD downgraded, Nike upgraded: Wall Street's top analyst calls
Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know
In the latest trading session, Gilead Sciences (GILD) closed at $89.14, marking a -1.64% move from the previous day.
Gilead Sciences (GILD) Stock Declines While Market Improves: Some Information for Investors
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $91.41, denoting a -0.51% change from the preceding trading day.
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
Gilead Sciences to Present at Upcoming Investor Conference
Gilead Stock Gains 15.4% in a Year: Should You Buy, Sell or Hold?
GILD has put up a steady performance in 2024, with a new drug approval, positive data readouts and strong quarterly results. We believe there is more room for growth, given GILD's strong fundamentals.
Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?
Here is how Atossa Genetics Inc. (ATOS) and Gilead Sciences (GILD) have performed compared to their sector so far this year.
Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study?
The company is still planning to move into Phase 3 testing, but analysts doubt the pain drug's future.
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
In the most recent trading session, Gilead Sciences (GILD) closed at $91.09, indicating a +0.44% shift from the previous trading day.
